Arca
Skip to content

Mucopolysaccharidosis type ii (mps ii)

Drug research and approvals for mucopolysaccharidosis type ii (mps ii): what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 16, 2026, 8 studies of mucopolysaccharidosis type ii (mps ii) are recruiting on ClinicalTrials.gov, Health Canada has authorized 5 drug trials for it since 2013, FDA has 2 approved and 4 open orphan designations naming it, and the EU has 1 authorised medicine for it.

  • Recruiting worldwide: 8
  • Trials authorized in Canada: 5
  • FDA orphan approvals: 2
  • EU medicines: 1

Recruiting Now

Newest start dates first, of 8 recruiting on ClinicalTrials.gov ↗

Trials Authorized in Canada

Newest first; search them all in Canada trials
Oct 31, 2024Effect of adalimumab on musculoskeletal disease in mucopolysaccharidosis types i, ii, iva and viHUMIRALUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTEROngoing
Oct 30, 2023An open-label extension to investigate the long-term safety, tolerability, and efficacy of dnl310 in patients with mucopolysaccharidosis type ii (mps ii) from…DNL310Denali Therapeutics Inc.Ongoing
Oct 26, 2022A phase 1/2/3 multicenter, open label study to evaluate the efficacy, safety, tolerability, and pharmacodynamics of rgx-121 in pediatric subjects with mps ii…RGX-121 / RAPAMUNE / PROGRAF / PREDNISOLONE / MEDROLREGENXBIOClosed
Jul 13, 2022A phase 1 open-label dose escalation study to evaluate the safety and efficacy of hmi-203 in enzyme replacement therapy (ert)-treated adults with…HMI-203 / DEXAMETHASONE / TACROLIMUS ER (ADVAGRAF)HOMOLOGY MEDICINES, INC.Closed
Jun 7, 2022A phase 2/3, multicenter, double-blind, randomized study to determine the efficacy and safety of dnl310 vs idursulfase in pediatric participants with…DNL310Denali Therapeutics Inc.Ongoing

FDA Orphan Designations

Approved first, then open designations, newest first
Mar 24, 2026Avlayahtreatment of neurologic manifestations of Hunter syndrome (Mucopolysaccharidosis type II, MPS II) when initiated in presymptomatic or…Denali Therapeutics Inc.Approved
Jul 24, 2006ElapraseIndicated for patients with Hunter syndrome (mucopolysaccharidosis II, MPS II). Idursulfase has been shown to improve walking capacity in…Takeda Pharmaceuticals U.S.A., Inc.Approved
Oct 16, 2025sleeping beauty transposon-engineered autologous…treatment of mucopolysaccharidosis type IIImmusoft CA, Inc.Designated
Oct 15, 2018Humanized IgG-1 antibody targeting human transferrin…Treatment of Mucopolysaccharidosis Type II (MPS II) or Hunter SyndromeJCR Pharmaceuticals Co., Ltd.Designated
Dec 8, 2015non-replicating recombinant adeno-associated virus (AAV)…Treatment of Mucopolysaccharidosis Type IIREGENXBIO, Inc.Designated
May 15, 2013HIRMAb-IDSTreatment of mucopolysaccharidosis Type II (Hunter Syndrome)ArmaGen Technologies, Inc.Designated

Medicines Authorised in the EU

Newest first
AuthorisedMedicineHolderEPAR
Jan 8, 2007ElapraseidursulfaseTakeda Pharmaceuticals International AG Ireland BranchEMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.